Sermorelin

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Sermorelin is a drug catalogued in DrugCentral. It was first approved by the FDA in 1990. DrugCentral lists 1 molecular target, including GHRHR. Recorded indications include Diagnostic Test for Growth Hormone Secretion and Pituitary dwarfism.

• Molecular targets: GHRHR (1 listed in DrugCentral).
• Indications: Diagnostic Test for Growth Hormone Secretion and Pituitary dwarfism.
• ATC code: H01AC04 (Somatropin and somatropin agonists).
• Molecular formula: C149H246N44O42S; molecular weight 3357.94 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diagnostic Test for Growth Hormone Secretion
• Pituitary dwarfism

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Growth hormone-releasing hormone receptor	GHRHR	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1990-12-28	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
H01AC04	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Somatropin and somatropin agonists
V04CD03	VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for pituitary function

Chemical structure

• Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular weight: 3357.94 g/mol
• CAS number: —
• InChIKey: WGWPRVFKDLAUQJ-MITYVQBRSA-N
• PubChem CID: 16132413

CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sermorelin used for?

DrugCentral lists the following indications for Sermorelin: Diagnostic Test for Growth Hormone Secretion and Pituitary dwarfism.

How does Sermorelin work?

Its molecular targets in DrugCentral include GHRHR (agonist).

When was Sermorelin first approved?

Sermorelin was first approved by the FDA in 1990.

What is the chemical formula of Sermorelin?

Sermorelin has the molecular formula C149H246N44O42S and a molecular weight of 3357.94 g/mol.

Sources

• DrugCentral drug card 2433 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201490 — compound record and bioactivity
• PubChem CID 16132413 — chemical identifiers
• DrugBank DB00010 — drug record
• FDA UNII 89243S03TE — substance identity
• DailyMed: FDA labels for Sermorelin — current prescribing information (label search)
• UniProt Q02643 (GHRHR) — target protein

How this page is built: methodology · editorial policy & corrections.